Search

Displaying results 7361 - 7370 of 9313 in total
  1. Drug

    Balicatib

    go.drugbank.com/drugs/DB12239
    Investigational

    Balicatib has been used in trials studying the treatment of Osteoporosis and Knee Osteoarthritis.

  2. Drug

    Carmegliptin

    go.drugbank.com/drugs/DB12268
    Investigational

    Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.

  3. Drug

    Muscimol

    go.drugbank.com/drugs/DB12458
    Investigational

    Muscimol has been used in trials studying the treatment of Epilepsy and Parkinson's Disease.

  4. Drug

    Acotiamide

    go.drugbank.com/drugs/DB12482
    Investigational

    Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.

  5. Drug

    Letrazuril

    go.drugbank.com/drugs/DB12663
    Investigational

    Letrazuril has been used in trials studying the treatment of HIV Infections and Cryptosporidiosis.

  6. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.

  7. Drug

    Daledalin

    go.drugbank.com/drugs/DB09189
    Experimental

    It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.

  8. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

  9. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906 … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination

  10. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.